Medical Technology, or MedTech for short, refers to technologies that diagnose, treat and improve human health care.
With supportive government policies and a strong manufacturing sector, Singapore is growing to becoming a regional MedTech hub. Singapore is already home to more than 60 multinational MedTech corporations, which engage in activities including manufacturing operations, research and development, as well as being the regional headquarters.
With global trends like consumers taking a more proactive approach to pursue healthier lifestyles and higher quality medical care, as well as a growing aging populations in Asia and the world, demand for MedTech is expected to increase.
SGX currently lists 35 healthcare and healthcare-related stocks and trusts that have a combined market capitalisation of over $60 billion.
Among them are four with MedTech-related businesses: Clearbridge Health, Techcomp Holdings, Vicplas International and QT Vascular, which together have a market capitalisation of $413 million. We will take closer a look at these companies for this week’s episode of 4 Stocks This Week.
Clearbridge Health Limited (SGX: 1H3)
Clearbridge Health Limited operates as a healthcare company that focuses on the delivery of precision medicine in Asia. It offers laboratory testing services comprising clinical diagnostics, as well as lifestyle and wellness management testing services; owns and operates medical centres; and invests in precision medical technology companies.
It recently announced that it has completed the acquisition of a 65% equity interest in a Philippines healthcare services provider, Marzan Healthcare Inc. Located in Quezon City, Marzan operates the Marzan Healthcare Diagnostic Center, a modern and well-equipped facility which provides a wide range of services including pathology services, imaging diagnostics, dental care, as well as dialysis and renal care.
Clearbridge Health said that it intends to tap on Marzan’s existing network to distribute its suite of precision medicine products and services to benefit from revenue synergies within the group.
“With our strong expertise in precision medicine and our patient-centric approach to healthcare, coupled with the local expertise of Marzan, we are confident that we can capitalize on the opportunities in the Philippine medical sector to deliver the best-in-class treatment and experience for our patients,” Clearbridge Health CEO Jeremy Yee said.
Clearbridge debuted on the Catalist board in December 2017 at $0.28 per share. It closed this week at $0.53, which is an increase of 89.3% from its IPO price.
Techcomp (Holdings) Limited (SGX: T43)
Techcomp (Holdings) Limited is in the business of designing, manufacturing, and distribution of analytical instruments, life science equipment, and laboratory instruments around the world, including China, Asia, Europe, the United States, Africa, and Australia. In China, it has 14 distribution branch offices.
Serving research institutes, universities, commercial companies, and government agencies, the company sells its products under the brands of Techcomp, Dynamica, Froilabo, IXRF, Precisa, Edinburgh, Scion, and more. Techcomp (Holdings) Limited is headquartered in Hong Kong.
Techcomp closed this week at $0.39.
Vicplas International Ltd (SGX: 569)
Vicplas International Ltd researches, designs, and manufactures medical devices in Singapore, Malaysia, and China through their subsidiary, Forefront Medical Technology (Pte) Ltd, which is registered under the United States Food and Drug Administration Medical Device Establishment as an approved contract manufacturer.
As a side note, Vicplas also designs, manufactures and distributes piping systems across diverse industries (ranging from waste management to telecommunications) under the VicPlas brand in Singapore, the Middle East, Bangladesh, and Asia Pacific.
After starting business operations in 1993, the Vicplas Group listed on the SGX SESDAQ (today known as Catalist) on April 22, 1999 and transferred to the SGX Mainboard on January 12, 2009.
It closed this week at $0.109, which is a year-to-date gain of about 11%.
QT Vascular Ltd. (SGX: 5I0)
QT Vascular Ltd. and its subsidiaries, designs, assembles, and distributes therapeutic solutions to address specific unmet clinical needs in the treatment of complex vascular disease in a minimally invasive manner.
The company offers coronary products, like balloon catheters and other products for the treatment of complex lesions, blocked arteries, distal peripheral vessels. The company utilises a direct sales approach for its product distribution.
Based in Singapore, it has operations in the United States, Singapore, Japan, Europe, China, Australia, and Hong Kong.
On 15 November 2017, QT Vascular announced that it reached a confidential settlement with AngioScore, Inc, which will “fully and finally resolve all past, present or future disputes concerning the subject matter of the pending or previously litigated matters between the group and AngioScore”. The stock price of QT Vascular surged following news of the settlement.
This week, it closed at $0.017, a year-to-date increase of about 42%.
To stay up to date with the latest news on the Singapore Exchange, do check out the SGX My Gateway Market Updates to get more insights.
4 Stocks This Week is not a recommendation from us to buy or sell any of these stocks. For investors who are keen to find out more, you should continue researching about them before making your investment decisions.